18R-H(p)EPE

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 18R-H(p)EPE
• 英文别名: 18R-HpEPE；(5Z,8Z,11Z,14Z,16E,18R)-18-hydroperoxyicosa-5,8,11,14,16-pentaenoic acid
• 化学式: C₂₀H₃₀O₄
• 分子量: 334.456
• InChiKey: ZNUBMQUXCKZUTC-UAAZXLHOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  18R-H(p)EPE 在 human PMN 5-lipoxygenase 作用下， 生成 5S-hydroperoxy, 18R-hydroxy-EPE
  参考文献：
  名称：

  [EN] USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
  [FR] UTILISATION DE DOCOSATRIENES, RESOLVINES ET LEURS ANALOGUES STABLES POUR LE TRAITEMENT DE MALADIES DES VOIES RESPIRATOIRES ET DE L'ASTHME

  摘要：

  公开号：

  WO2005089744A3
• 作为产物：
  描述：

  全顺式二十碳五烯酸 在 cyclooxygenase-II 、 阿司匹林 作用下， 生成 18R-H(p)EPE
  参考文献：
  名称：

  [EN] USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
  [FR] UTILISATION DE DOCOSATRIENES, RESOLVINES ET LEURS ANALOGUES STABLES POUR LE TRAITEMENT DE MALADIES DES VOIES RESPIRATOIRES ET DE L'ASTHME

  摘要：

  公开号：

  WO2005089744A3

文献信息

• Resolvins: Biotemplates for therapeutic interventions
  申请人：BRIGHAM AND WOMEN'S HOSPITAL

  公开号：EP2216318A2

  公开（公告）日：2010-08-11

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

  本发明一般涉及新型分离治疗剂，称为 resolvins，由膳食中的ω-3 多不饱和脂肪酸（PUFA）如二十碳五烯酸（EPA）或二十二碳六烯酸（DHA）、环氧化酶-II（COX-2）和镇痛剂如阿司匹林（ASA）之间的相互作用产生。令人惊奇的是，在适当的环境中仔细分离由各种成分组合产生的化合物，可以得到具有独特结构和生理特性的二羟基和三羟基 EPA 或 DHA 化合物。因此，本发明提供了许多新的有用的 EPA 或 DHA 的二羟基或三羟基治疗性衍生物（resolvins），这些衍生物可减轻、预防或消除炎症或 PMN 迁移等。本发明还提供了整个说明书中公开的化合物的使用方法、制备方法和用作药物的包装药品。
• RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS
  申请人：SERHAN CHARLES N.

  公开号：US20100016432A1

  公开（公告）日：2010-01-21

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
• RESOLVINS: BIOEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS
  申请人：Serhan Charles N.

  公开号：US20130217771A1

  公开（公告）日：2013-08-22

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
• US7585856B2
  申请人：——

  公开号：US7585856B2

  公开（公告）日：2009-09-08
• [EN] USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA<br/>[FR] UTILISATION DE DOCOSATRIENES, RESOLVINES ET LEURS ANALOGUES STABLES POUR LE TRAITEMENT DE MALADIES DES VOIES RESPIRATOIRES ET DE L'ASTHME
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2005089744A3

  公开（公告）日：2006-01-12